Trump announces trade deal with EU following months of negotiations
SAN DIEGO - Connect Biopharma Holdings Limited (NASDAQ:CNTB), a clinical-stage biopharmaceutical company with a market capitalization of $47.23 million, presented clinical data showing its experimental antibody rademikibart improved lung function and reduced asthma exacerbations in patients with eosinophilic-driven type 2 asthma, according to a press release statement. InvestingPro analysis suggests the company is currently undervalued, with analysts anticipating sales growth in the current year despite ongoing development expenses.
The data, presented Friday at the European Academy of Allergy and Clinical Immunology Annual Congress in Glasgow, demonstrated that rademikibart rapidly improved lung function within the first week of treatment, with effects sustained through 24 weeks.
Post-hoc analyses of the company’s Phase 2b trial showed the treatment reduced annualized asthma exacerbation rates by 63% in patients with elevated baseline eosinophils, 69% in those with elevated fractional exhaled nitric oxide (FeNO), and 74% in patients with both markers elevated.
The analyses focused on patients with type 2 inflammation markers, including those with elevated baseline eosinophil counts of ≥150 or ≥300 cells/µL and elevated FeNO ≥25 ppb. While the clinical results appear promising, InvestingPro data reveals the company maintains a strong liquidity position with a current ratio of 10.25, though it is currently burning through cash reserves to fund its development programs.
Patients receiving rademikibart also showed improvements in Asthma Control Questionnaire scores compared to placebo, particularly in subgroups with elevated eosinophil counts.
The company noted that treatment groups had lower reports of high post-baseline eosinophil counts compared to published data for dupilumab, another IL-4 receptor alpha antibody.
Connect Biopharma is currently conducting Phase 2 studies of rademikibart for acute exacerbations in both asthma and chronic obstructive pulmonary disease (COPD), with topline data expected in the first half of 2026.
The San Diego-based biopharmaceutical company is developing rademikibart as a potential treatment for the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. With a beta of -0.27, the stock tends to move counter to market trends, potentially offering portfolio diversification benefits. For deeper insights into Connect Biopharma’s financial health and growth prospects, including additional ProTips and detailed metrics, visit InvestingPro.
In other recent news, Connect Biopharma Holdings Limited has initiated its Phase 2 Seabreeze STAT Asthma study, following approval from the U.S. Food and Drug Administration. This trial aims to evaluate the safety and efficacy of rademikibart as an add-on therapy for acute asthma exacerbations, with topline data anticipated in the first half of 2026. Additionally, the FDA has greenlit Phase 2 trials for rademikibart targeting moderate-to-severe asthma or COPD, with results expected in the same timeframe. H.C. Wainwright has maintained a Buy rating with an $8 price target on Connect Biopharma, highlighting the potential of rademikibart in addressing acute exacerbations. The firm projects global peak sales of $2.3 billion by 2038, considering a 25% probability. Meanwhile, Connect Biopharma has been notified by Nasdaq regarding its stock price falling below the minimum required for continued listing, with a deadline to regain compliance by September 22, 2025. Despite this, the company continues its research and development efforts, focusing on rademikibart’s potential in treating asthma and COPD exacerbations. These developments underscore Connect Biopharma’s ongoing commitment to advancing treatments in respiratory care.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.